Literature DB >> 6481388

Multiple sclerosis presenting with progressive visual failure.

I E Ormerod, W I McDonald.   

Abstract

Progressive visual failure as the presenting feature of multiple sclerosis is described in five patients. The clinical features did not permit a distinction from visual loss due to compression. The finding of oligoclonal bands in the CSF at presentation is a useful pointer to the diagnosis, but is not specific and full investigation to exclude treatable causes of visual loss is essential.

Entities:  

Mesh：

Year:  1984        PMID： 6481388      PMCID： PMC1027995          DOI： 10.1136/jnnp.47.9.943

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  10 in total

1.  Ophthalmic aspects of demyelinating diseases.

Authors:  G I SCOTT
Journal:  Proc R Soc Med       Date:  1961-01

2.  Optic neuritis in relation to demyelinating diseases; a clinical study.

Authors:  A SCHLOSSMAN; C C PHILLIPS
Journal:  Am J Ophthalmol       Date:  1954-04       Impact factor: 5.258

3.  Slowly progressive and acute visual impairment in multiple sclerosis.

Authors:  E Kahana; U Leibowitz; N Fishback; M Alter
Journal:  Neurology       Date:  1973-07       Impact factor: 9.910

4.  Oligoclonal immunoglobulins and plasma cells in spinal fluid of patients with multiple sclerosis.

Authors:  E J Thompson; P Kaufmann; R C Shortman; P Rudge; W I McDonald
Journal:  Br Med J       Date:  1979-01-06

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Remyelination during optic nerve compression.

Authors:  R E Clifford-Jones; D N Landon; W I McDonald
Journal:  J Neurol Sci       Date:  1980-05       Impact factor: 3.181

7.  The symptomatology of tumours of the anterior visual pathways.

Authors:  W I McDonald
Journal:  Can J Neurol Sci       Date:  1982-11       Impact factor: 2.104

8.  Chronic retrobulbar and chiasmal neuritis.

Authors:  B Ashworth
Journal:  Br J Ophthalmol       Date:  1967-10       Impact factor: 4.638

9.  The clinical picture of ectasia of the intracerebral arteries.

Authors:  Y L Yu; I F Moseley; P Pullicino; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-01       Impact factor: 10.154

10.  Sphenoid sinusitis. A review of 30 cases.

Authors:  D Lew; F S Southwick; W W Montgomery; A L Weber; A S Baker
Journal:  N Engl J Med       Date:  1983-11-10       Impact factor: 91.245
  10 in total
  5 in total

Review 1.  The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system.

Authors:  W I McDonald; D Barnes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

2.  A preliminary longitudinal study of the retinal nerve fiber layer in progressive multiple sclerosis.

Authors:  Andrew P D Henderson; S A Trip; P G Schlottmann; D R Altmann; D F Garway-Heath; G T Plant; D H Miller
Journal:  J Neurol       Date:  2010-02-09       Impact factor: 4.849

3.  Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.

Authors:  G V McDonnell; S A Hawkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

4.  Autoimmune optic neuropathy: evaluation and treatment.

Authors:  M J Kupersmith; R M Burde; F A Warren; T G Klingele; L P Frohman; H Mitnick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-11       Impact factor: 10.154

5.  MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Ayman Tourbah; Olivier Gout; Alain Vighetto; Véronique Deburghgraeve; Jean Pelletier; Caroline Papeix; Christine Lebrun-Frenay; Pierre Labauge; David Brassat; Ahmed Toosy; David-Axel Laplaud; Olivier Outteryck; Thibault Moreau; Marc Debouverie; Pierre Clavelou; Olivier Heinzlef; Jérôme De Sèze; Gilles Defer; Frédéric Sedel; Carl Arndt
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.